(MENAFN- GlobeNewsWire - Nasdaq) Key opportunities in the DOACs device market include rising personalized medicine adoption, home-based management preference, rapid diagnostics demand, and emerging market infrastructure. Innovations in smart sensor integration, point-of-care testing, and device compliance present growth prospects amid regulatory and trade challenges.

Dublin, Nov. 04, 2025 (GLOBE NEWSWIRE) -- The "Direct Oral Anticoagulants (DOACs) Device Market Report 2025" report has been added to ResearchAndMarkets's offering.
The direct oral anticoagulants (DOACs) device market size has grown strongly in recent years. It will grow from $30.1 billion in 2024 to $32.8 billion in 2025 at a compound annual growth rate (CAGR) of 9%. The growth in the historic period can be attributed to the rising prevalence of cardiovascular disorders, increasing incidence of atrial fibrillation, growing awareness of stroke prevention, rising anticoagulant prescriptions, and the expanding geriatric population. The direct oral anticoagulants (DOACs) device market size is expected to see strong growth in the next few years. It will grow to $45.65 billion in 2029 at a compound annual growth rate (CAGR) of 8.6%.

The growth in the forecast period can be attributed to increasing adoption of personalized medicine, rising preference for home-based anticoagulant management, growing demand for rapid diagnostic tools, expanding awareness of stroke prevention, and development of healthcare infrastructure in emerging markets. Major trends during this period include integration of smart sensors into monitoring devices, development of point-of-care direct oral anticoagulant testing tools, continuous innovation in drug delivery systems, incorporation into routine clinical workflows, and advancements in patient compliance technologies.
The rising prevalence of cardiovascular disorders is expected to drive the growth of the direct oral anticoagulants (DOACs) device market going forward. Cardiovascular disorders encompass conditions that affect the heart and blood vessels, often causing heart attacks, strokes, or other circulatory complications. The increase in these disorders is driven by increasingly sedentary lifestyles, which contribute to weight gain, high blood pressure, and weakened cardiovascular function over time.

Direct oral anticoagulants (DOACs) help manage cardiovascular conditions by reducing the risk of stroke and blood clots in patients with atrial fibrillation, providing effective anticoagulation without frequent blood monitoring. For example, in January 2025, the American Heart Association, a US-based nonprofit organization, reported that cardiovascular disease caused 941,652 deaths in the US in 2022, an increase from 931,578 deaths in 2021. Therefore, the growing prevalence of cardiovascular disorders is fueling the growth of the direct oral anticoagulants (DOACs) device market.
Companies in the direct oral anticoagulants (DOACs) device market are developing advanced solutions, such as automated coagulation assays, to enhance the accuracy, efficiency, and consistency of anticoagulant monitoring in clinical laboratories. Automated coagulation assays are laboratory tests performed by machines to measure blood clotting speed, aiding in the diagnosis of bleeding or clotting disorders.

For instance, in February 2024, Roche Holding AG, a Switzerland-based pharmaceutical company, launched three coagulation tests designed specifically for Factor Xa inhibitors. These tests allow clinicians to accurately assess the anticoagulation status of patients taking rivaroxaban, apixaban, edoxaban, and heparin, supporting critical decisions during bleeding events, overdoses, or urgent surgeries. Using Roche's reagent cassette technology on cobas t analyzers, these automated assays deliver reliable results, reduce manual handling, and optimize laboratory workflow efficiency.
In July 2024, Perosphere Technologies Inc., a US-based medical diagnostics company, partnered with CoRRect Medical to exclusively distribute its reagent-free point-of-care coagulometer in Germany. This partnership aims to meet unmet needs in coagulation testing by enabling rapid bedside assessment of anticoagulation status, particularly for patients on direct oral anticoagulants, improving treatment decisions, patient outcomes, and reducing healthcare costs. CoRRect Medical is a Germany-based medical device company.
Major players in the direct oral anticoagulants (DOACs) device market are Pfizer Inc., Roche Diagnostics Corporation, Bristol-Myers Squibb Company, Siemens Healthcare GmbH, Becton Dickinson And Company, Boehringer Ingelheim International GmbH, Teva Pharmaceutical Industries Limited, Daiichi Sankyo Co. Ltd, Sysmex Corporation, Dr. Reddy's Laboratories Limited, Werfen S.A., Alembic Pharmaceuticals Limited, Diagnostica Stago SAS, Helena Laboratories Corporation, iLine Microsystems S.L., Technoclone GmbH, Anthos Therapeutics Inc., FLoBio LLC, Perosphere Technologies Inc., and DOASENSE GmbH.
North America was the largest region in the direct oral anticoagulants (DOACs) device market in 2024. The regions covered in direct oral anticoagulants (DOACs) device market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East and Africa. The countries covered in the direct oral anticoagulants (DOACs) device market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA, Canada, Italy, Spain.
Note that the outlook for this market is being affected by rapid changes in trade relations and tariffs globally. The report will be updated prior to delivery to reflect the latest status, including revised forecasts and quantified impact analysis. The report's Recommendations and Conclusions sections will be updated to give strategies for entities dealing with the fast-moving international environment.

Key Attributes:

Report Attribute	Details
No. of Pages	250
Forecast Period	2025 - 2029
Estimated Market Value (USD) in 2025	$32.8 Billion
Forecasted Market Value (USD) by 2029	$45.65 Billion
Compound Annual Growth Rate	8.6%
Regions Covered	Global

Reasons to Purchase:

• Gain a truly global perspective with the most comprehensive report available on this market covering 15 geographies.
• Assess the impact of key macro factors such as geopolitical conflicts, trade policies and tariffs, post-pandemic supply chain realignment, inflation and interest rate fluctuations, and evolving regulatory landscapes.
• Create regional and country strategies on the basis of local data and analysis.
• Identify growth segments for investment.
• Outperform competitors using forecast data and the drivers and trends shaping the market.
• Understand customers based on the latest market shares.
• Benchmark performance against key competitors.
• Suitable for supporting your internal and external presentations with reliable high quality data and analysis
• Report will be updated with the latest data and delivered to you along with an Excel data sheet for easy data extraction and analysis.
• All data from the report will also be delivered in an excel dashboard format.

Scope

• Product: Factor Xa Inhibitors; Direct Thrombin Inhibitors
• Disease: Atrial Fibrillation; Deep Vein Thrombosis; Pulmonary Embolism; Heart Attacks; Post-Surgical Thromboprophylaxis; Other Diseases
• Application: Stroke Prevention; Venous Thromboembolism Prevention; Treatment of Acute Thrombotic Events; Long-Term Prophylaxis; Other Applications
• End User: Hospitals; Ambulatory Surgical Centers; Specialty Clinics; Homecare Settings; Other End Users

Subsegments:

• Factor Xa Inhibitors: Rivaroxaban Monitoring Devices; Apixaban Monitoring Devices; Edoxaban Monitoring Devices; Betrixaban Monitoring Devices
• Direct Thrombin Inhibitors: Dabigatran Etexilate; Dabigatran Mesylate

Companies Featured

• Pfizer Inc.
• Roche Diagnostics Corporation
• Bristol-Myers Squibb Company
• Siemens Healthcare GmbH
• Becton Dickinson And Company
• Boehringer Ingelheim International GmbH
• Teva Pharmaceutical Industries Limited
• Daiichi Sankyo Co. Ltd
• Sysmex Corporation
• Dr. Reddy's Laboratories Limited
• Werfen S.A.
• Alembic Pharmaceuticals Limited
• Diagnostica Stago SAS
• Helena Laboratories Corporation
• iLine Microsystems S.L.
• Technoclone GmbH
• Anthos Therapeutics Inc.
• FLoBio LLC
• Perosphere Technologies Inc.
• DOASENSE GmbH

For more information about this report visit

About is the world's leading source for international market research reports and market data. We provide you with the latest data on international and regional markets, key industries, the top companies, new products and the latest trends.

Attachment

• Direct Oral Anticoagulants (DOACs) Device Market

CONTACT: CONTACT: Laura Wood,Senior Press Manager... For E.S.T Office Hours Call 1-917-300-0470 For U.S./ CAN Toll Free Call 1-800-526-8630 For GMT Office Hours Call +353-1-416-8900

MENAFN04112025004107003653ID1110293627